Personal Research Database Bibliometric

Full Text: 2014\Tum Bio35, 1203.pdf

Abstract: Published data regarding the association between XPG Asp1104His polymorphism and bladder cancer risk remained controversial. This meta-analysis of literatures was performed to draw a more precise estimation of the relationship. We systematically searched PubMed, Embase, and Web of Science with a time limit of June 22, 2013. Summary odds ratios (ORs) with 95 % CIs were used to assess the strength of the association between XPG Asp1104His polymorphism and bladder cancer risk using random effects model. A total of eight case-control studies including 2,613 cases and 2,934 controls were included for analysis. Overall, no significant association was found between XPG Asp1104His polymorphism and bladder cancer susceptibility for CC vs. GG (OR = 1.12, 95 % CI = 0.74-1.69), GC vs. GG (OR = 1.12, 95 % CI = 0.86-1.46), The dominant model CC + GC vs. GG (OR = 1.08, 95 % CI = 0.85-1.38), and the recessive model CC vs. GC + GG (OR = 0.92, 95 % CI = 0.66-1.29). In the subgroup analysis, no significant associations were found in either Asian or non-Asian population. This meta-analysis suggested that XPG Asp1104His polymorphism was not associated with bladder cancer risk.

Keywords: Analysis, Asian, Assessment, Association, Bias, Bladder, Bladder Cancer, Cancer, Cancer Risk, Case-Control, Case-Control Studies, Data, Disease, Dna-Repair, Effects, Expression, Genetic Association, Meta Analysis, Meta-Analysis, Metaanalysis, Model, Models, Nucleotide Excision-Repair, Pathway, Polymorphism, Population, Pubmed, Quantitative Assessment, Random Effects Model, Risk, Science, Strength, Web of Science, XPG ASP1104HIS

? Xiao, J.C., He, X.Y., Wang, Z.Y., Hu, J.Y., Sun, F., Qi, F., Yang, S.G. and Xiao, Z.Y. (2014), Serum carbohydrate antigen 19-9 and prognosis of patients with gastric cancer. Tumor Biology, 35 (2), 1331-1334.

Full Text: 2014\Tum Bio35, 1331.pdf

Abstract: Previous studies have assessed the prognostic role of serum carbohydrate antigen 19-9 (CA 19-9) concentration in patients with gastric cancer, but the findings from those studies were inconsistent. We searched the PubMed and Web of Science databases to find eligible studies assessing the prognostic role of CA 19-9 in patients with gastric cancer. Twelve studies with a total of 5,072 gastric cancer patients were finally included into the meta-analysis. The pooled hazard ratio (HR) with corresponding 95 % confidence interval (95 % CI) for overall survival were calculated to assess the prognostic role of CA 19-9 in patients with gastric cancer. Overall, elevated serum concentration of CA 19-9 (> 37 U/mL) was associated with poorer overall survival in patients with gastric cancer (fixed-effects HR = 1.36, 95 % CI 1.24-1.48, P < 0.001). Subgroup analysis by study design further showed that elevated serum concentration of CA 19-9 was associated with poorer overall survival in patients with gastric cancer. There was no obvious risk of publication bias. Elevated concentration of serum CA 19-9 is associated with poorer overall survival in patients with gastric cancer.

Keywords: Analysis, Assessing, Bias, Ca 19-9, Ca-19-9, Ca72-4, Cancer, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, Cea, Clinical-Significance, Concentration, Confidence, Databases, Design, Gastric, Gastric Cancer, Hazard, Interval, Meta Analysis, Meta-Analysis, Metaanalysis, P, Patients, Perspectives, Prognosis, Prognostic, Publication, Publication Bias, Pubmed, Risk, Role, Science, Serum, Study Design, Survival, Tumor-Markers, Web of Science, Web of Science Databases

? Ma, Q.T., Zhao, Y.M., Wang, S.F., Zhang, X.Y., Zhang, J.L., Du, M., Li, L. and Zhang, Y. (2014), Genetic polymorphisms of XRCC3 Thr241Met (C18067T, rs861539) and bladder cancer risk: A meta-analysis of 18 research studies. Tumor Biology, 35 (2), 1473-1480.

Full Text: 2014\Tum Bio35, 1473.pdf

Abstract: the relationship of bladder cancer with the presence of X-ray cross-complementing group 3(XRCC3) genetic polymorphismThr241Met has been reported with inconsistent results. The objective of this study was to quantitatively evaluate the association between this polymorphism and bladder cancer susceptibility. A comprehensive research was conducted through PubMed, Medline, Embase, and Web of Science databases up to Aug. 20, 2013. Pooled odds ratio and 95 % confidence interval were calculated using a fixed or random effects model. Statistical analysis was performed with Stata 12.0 software. of the 18 case-control studies selected for this meta-analysis, a total of 5,667 bladder cancer cases and 7,609 controls were included. The combined results based on all studies suggested that XRCC3 Thr241Met was associated with bladder cancer risk under homozygote and recessive models. When stratifying for ethnicity, significant association was found in Caucasians under homozygote and recessive models. This meta-analysis suggests that XRCC3 Thr241Met polymorphism is a risk factor for bladder cancer risk. However, further well-designed studies are required to confirm our findings.

Keywords: Analysis, Association, Associations, Bias, Bladder, Bladder Cancer, Cancer, Cancer Risk, Case-Control, Case-Control Studies, Cohort, Confidence, Databases, Dna-Repair Genes, Effects, Ethnicity, Exposure, Genetic, Interval, Medline, Meta Analysis, Meta-Analysis, Metaanalysis, Model, Models, Odds Ratio, Polymorphism, Polymorphisms, Pubmed, Random Effects Model, Research, Risk, Risk Factor, Science, Smoking, Software, Stata, Statistical Analysis, Susceptibility, Web of Science, Web of Science Databases, X-Ray, XPD, XRCC3

? Xu, H.B., Yang, H., Liu, T.T. and Chen, H. (2014), Association of CTLA4 gene polymorphism (rs5742909) with cervical cancer: A meta-analysis. Tumor Biology, 35 (2), 1605-1608.

Full Text: 2014\Tum Bio35, 1605.pdf

Abstract: Previous studies suggested that CTLA4 polymorphism (rs5742909) is associated with susceptibility to cervical cancer. In the present study, we performed a meta-analysis to systematically summarize the possible association between rs5742909 and the risk for cervical cancer. We conducted a search of case-control studies on the associations of rs5742909 with susceptibility to cervical cancer in PubMed, EMBASE, ISI Web of Science, Cochrane Central Register of Controlled Trials, Wanfang database in China, and Chinese National Knowledge Infrastructure databases. We extracted the data from eligible studies for meta-analysis. The association of cervical cancer risk with rs5742909 was estimated by pooled odds ratios (ORs) and 95 % confidence intervals (95 % CIs). There were four studies on rs5742909 and cervical cancer in our meta-analysis. Our results suggested that both T allele frequency (OR = 1.63, 95 % CI 1.06-2.50; P = 0.03) and (TT + CT) genotype distribution (OR = 1.72, 95 % CI 1.07-2.77; P = 0.03) of the rs5742909 were associated with risk for cervical cancer. This meta-analysis suggests that rs5742909 is associated with the risk of cervical cancer. Well-designed studies with larger sample size and more ethnic groups are required to further validate the results.

Keywords: Association, Cancer, Cancer Risk, Case-Control, Case-Control Studies, Cervical Cancer, China, Chinese, Confidence, Confidence Intervals, Ct, Ctla4, Data, Database, Databases, Distribution, Embase, Ethnic Groups, Exon-1 Polymorphisms, Expression, Gene, Gene Polymorphism, Groups, Intervals, Isi, Isi Web of Science, Knowledge, Meta Analysis, Meta-Analysis, Metaanalysis, P, Polymorphism, Population, Promoter, Pubmed, Risk, Sample Size, Science, Size, Susceptibility, Web of Science

? Wang, L.C., Liu, Z.H., Jing, P.W., Shao, L., Chen, L., He, X. and Gong, W.X. (2014), Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: A systemic review and meta-analysis. Tumor Biology, 35 (2), 1649-1652.

Full Text: 2014\Tum Bio35, 1649.pdf

Abstract: Murine double minute 2 (MDM2) plays an important role in the carcinogenesis of many cancers including osteosarcoma. We performed a systemic review and meta-analysis to assess the effects of MDM2 polymorphisms on osteosarcoma risk and survival of patients with osteosarcoma. PubMed, Web of Science, and Wanfang databases were searched for eligible studies on the associations of MDM2 polymorphisms with osteosarcoma risk and survival of patients with osteosarcoma. Pooled odds ratio (OR) or hazard ratio (HR) with 95 % confidence intervals (95 % CIs) was used to assess the effects of MDM2 polymorphisms on osteosarcoma risk and survival of patients with osteosarcoma. Overall, MDM2 rs2279744 polymorphism was associated with a risk of osteosarcoma (allele model, OR = 1.60, 95 % CI 1.23-2.07, P < 0.001; codominant model, OR = 2.47, 95 % CI 1.46-4.19, P = 0.001; recessive model, OR = 2.13, 95 % CI 1.32-3.46, P = 0.002; dominant model, OR = 1.61, 95 % CI 1.12-2.33, P = 0.01). MDM2 rs1690916 polymorphism was also associated with a risk of osteosarcoma (OR = 0.60, 95 % CI 0.46-0.77, P < 0.001). However, MDM2 rs2279744 polymorphism was not associated with the overall survival of patients with osteosarcoma (codominant model, HR = 1.01, 95 % CI 0.53-1.91, P = 0.98; recessive model, HR = 1.07, 95 % CI 0.54-2.11, P = 0.85; dominant model, HR = 1.04, 95 % CI 0.65-1.66, P = 0.87). The meta-analysis suggests that MDM2 polymorphisms have some effects on the risk of osteosarcoma but have no effect on the survival of patients with osteosarcoma. Future studies are needed to further assess the effects of MDM2 polymorphisms on the risk and survival of osteosarcoma.

Keywords: Cancer, Confidence, Confidence Intervals, Databases, Effects, Hazard, Intervals, Mdm2, Meta Analysis, Meta-Analysis, Metaanalysis, Model, Odds Ratio, Osteosarcoma, P, P53, Patients, Polymorphism, Polymorphisms, Pubmed, Review, Risk, Role, Science, Suppressor, Survival, Web of Science

? Liang, H.J., Yan, Y.L., Li, T.J., Li, R.L., Li, M., Li, S. and Qin, X. (2014), Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk in Chinese population: A meta-analysis of 22 case-control studies. Tumor Biology, 35 (2), 1695-1701.

Full Text: 2014\Tum Bio35, 1695.pdf

Abstract: the association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and breast cancer risk in the Chinese population has been widely reported, but results were inconsistent. In order to derive a more precise estimation of the relationship, a meta-analysis was performed. Eligible articles were identified through search of databases including Medline, PubMed, Web of Science, Embase, Chinese Biomedical Literature Database (CBM, Chinese), China National Knowledge Infrastructure (CNKI, Chinese), and Wangfang Database (Chinese). The association between the MTHFR polymorphism and breast cancer risk was conducted using odds ratios (ORs) and 95 % confidence intervals (95 % CIs). Finally, a total of 22 studies with 6,103 cases and 7,913 controls were included in our meta-analysis: 13 studies with 3,273 cases and 4,419 controls for C677T polymorphism and 9 studies with 2,830 cases and 3,494 controls for A1298C polymorphism. With regard to C677T polymorphism, significant association was found with breast cancer risk under three models (T vs. C: OR = 1.12, 95 % CI = 1.02-1.23, P = 0.015; TT vs. CC: OR = 1.35, 95 % CI = 1.10-1.67, P = 0.005; TT vs. CC/CT: OR = 1.37, 95 % CI = 1.11-1.70, P = 0.004). There was no significant association found between A1298C polymorphism and breast cancer risk under all genetic models (C vs. A: OR = 0.96, 95 % CI = 0.89-1.03, P = 0.268; CC vs. AA: OR = 0.98, 95 % CI = 0.77-1.26, P = 0.899; AC vs. AA: OR = 0.95, 95 % CI = 0.88-1.02, P = 0.174; CC vs. AC/AA: OR = 1.00, 95 % CI = 0.78-1.28, P = 0.996, CC/AC vs. AA: OR = 0.96, 95 % CI = 0.89-1.02, P = 0.196). In summary, during this meta-analysis, we found that MTHFR C677T polymorphism was significantly associated with breast cancer risk in the Chinese population. Meanwhile, MTHFR A1298C polymorphism was not associated with breast cancer risk in the Chinese population.

Keywords: Association, Biomedical, Breast Cancer, Cancer, Cancer Risk, Case-Control, Case-Control Studies, China, Chinese, Confidence, Confidence Intervals, Database, Databases, Dietary-Folate Intake, Disease, Folic-Acid, Gene, Genetic, Intervals, Knowledge, Literature, Medline, Meta Analysis, Meta-Analysis, Metaanalysis, Methylenetetrahydrofolate Reductase, Models, Mortality, Mthfr C677t, Mthfr C677t Polymorphism, Nested-Case-Control, P, Polymorphism, Polymorphisms, Pooled Analyses, Population, Pubmed, Risk, Science, Taiwan, Web of Science

? Cai, K.M., Wang, Y., Zhao, X.J. and Bao, X.L. (2014), Association between the P53 codon 72 polymorphism and nasopharyngeal cancer risk. Tumor Biology, 35 (3), 1891-1897.

Full Text: 2014\Tum Bio35, 1891.pdf

Abstract: the P53 codon 72 polymorphism has been identified as a critical biomarker in modifying the risk of nasopharyngeal cancer (NPC). Many studies have investigated the association between the polymorphism of P53 codon 72 and NPC risk; however, the findings across the published studies are inconsistent and inconclusive. To acquire a more precise assessment for this association, we conducted an updated meta-analysis. The PubMed, Embase, Web of Science, and Wanfang databases were searched for relevant case-control studies. Totally, seven independent publications with 1,133 cases and 1,678 controls were retrieved. The pooled odds ratio (OR) with corresponding 95 % confidence interval (95 % CI) was calculated. Increased risk of NPC was observed among individuals carrying the variant allele and genotypes of P53 codon 72 (OR (Pro vs. Arg) = 1.32, 95 % CI 1.18-1.47, P (OR) < 0.001; OR (ProPro vs. ArgArg) = 1.90, 95 % CI 1.51-2.39, P (OR) < 0.001; OR (ProArg + ProPro vs. ArgArg) = 1.33, 95 % CI 1.13-1.57, P (OR) = 0.001; OR (ProPro vs. ArgArg + ProArg) = 1.65, 95 % CI 1.35-2.01, P (OR) < 0.001). Stratified analyses by ethnicity and source of controls also identified this significant relationship in Asians, Caucasians, and hospital-based case-control studies. There was no publication bias risk in our study. The updated meta-analysis supports the evidence that the polymorphism of P53 codon 72 is a risk factor for the development of NPC among the populations of both Asian and Caucasian.

Keywords: Analyses, Arg72pro Polymorphism, Asian, Assessment, Association, Bias, Biomarker, Cancer, Cancer Risk, Carcinoma, Case-Control, Case-Control Studies, Caucasian, Confidence, Databases, Development, Ethnicity, Evidence, Gene, Graphical Test, Interval, Mar, Meta Analysis, Meta-Analysis, Metaanalysis, Mutations, Nasopharyngeal Cancer, Odds Ratio, P, P53, P53 Codon 72, Polymorphism, Polymorphisms, Population, Populations, Protein, Publication, Publication Bias, Publications, Pubmed, Risk, Risk Factor, Science, Source, Susceptibility, Tp53, Web of Science

? Yan, Y.L., Liang, H.J., Light, M., Li, T.J., Deng, Y., Li, M., Li, S. and Qin, X. (2014), XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: A meta-analysis. Tumor Biology, 35 (3), 1907-1915.

Full Text: 2014\Tum Bio35, 1907.pdf

Abstract: the association between xeroderma pigmentosum complementation group D (XPD) Asp312Asn and Lys751Gln gene polymorphisms and breast cancer risk has been widely reported, but the results were inconsistent. In order to derive a more precise estimation of the relationship, a meta-analysis was performed. A comprehensive search strategy was conducted towards the electronic databases including Medline, PubMed, Web of Science, Embase, and Chinese Biomedical Literature Database (Chinese). The association between the XPD polymorphism and breast cancer risk was conducted by odds ratios (ORs) and 95 % confidence intervals (95 % CIs). A total of 22 studies with 18,136 cases and 18,351 controls were included in our meta-analysis. Among these, 12 studies with 7,667 cases and 7,480 controls for Asp312Asn polymorphism and 20 studies with 10,469 cases and 10,871 controls for Lys751Gln polymorphism. With regard to Asp312Asn polymorphism, no significantly associated was found with breast cancer risk. However, significant association was found between Lys751Gln polymorphism and breast cancer risk under all genetic models in overall populations (C vs. A-OR = 1.10, 95 % CI = 1.04-1.17, P = 0.002; CC vs. AA-OR = 1.17, 95 % CI = 1.06-1.30, P = 0.003; AC vs. AA-OR = 1.06, 95 % CI = 1.01-1.12, P = 0.032; CC vs. AC, AA-OR = 1.17, 95 % CI = 1.04-1.32, P = 0.009; CC, AC vs. AA-OR = 1.07, 95 % CI = 1.02-1.12, P = 0.005). In subgroup analysis base on ethnicity, significance was found in Caucasians and mix. The results suggest that XPD Asp312Asn polymorphism was not associated with breast cancer. The XPD Lys751Gln polymorphism significantly increased breast cancer risk, especially for Caucasian and mix.

Keywords: Adducts, Analysis, Association, Biomedical, Breast Cancer, Cancer, Cancer Risk, Caucasian, Chinese, Confidence, Confidence Intervals, Database, Databases, DNA-Repair Genes, Ethnicity, Gene, Genetic, Intervals, Literature, Mar, Medline, Meta Analysis, Meta-Analysis, Metaanalysis, Models, P, Phenotypes, Polymorphism, Polymorphisms, Population, Populations, Pubmed, Risk, Science, Search Strategy, Significance, Single-Nucleotide Polymorphisms, Smoking, Strategy, Web of Science, Women, XPD, XRCC1

? Yu, X., Huang, Y., Li, C.H., Yang, H.L., Lu, C.D. and Duan, S.W. (2014), Positive association between lymphotoxin-alpha variation rs909253 and cancer risk: A meta-analysis based on 36 case-control studies. Tumor Biology, 35 (3), 1973-1983.

Full Text: 2014\Tum Bio35, 1973.pdf

Abstract: Lymphotoxin-alpha (LTA) polymorphism rs909253 has been reported to be a risk factor for cancers, but some results are inconsistent. To establish a more conclusive association, we performed a meta-analysis of this variant with cancers. A systematic search was performed for informative case-control studies of rs909253 with cancers among literature databases, including PubMed, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), and Wanfang Chinese Periodical Database. After a comprehensive filtration procedure, 36 publications involved with 35,677 participants were selected for the current meta-analysis. Stratified factors, such as cancer type, populations, and source of control, were used for a better interpretation of this variant. Minimal heterogeneity was shown in the current meta-analysis (I (2) = 0.0 %, P = 0.48). Our results show a significant association of rs909253 and cancer risk (odds ratio (OR) = 1.12, P ((z)) < 0.001). In the subgroup analysis, significant association of rs909253 was found in adenocarcinoma (OR = 1.16, P ((z)) < 0.001) and hematological malignancy (OR = 1.10, P ((z)) < 0.001). Our meta-analyses established a significant association of rs909253 with cancer risk among multiple populations including North Americans, Asians, and Europeans.

Keywords: Adenocarcinoma, Analysis, Association, Breast-Cancer, Cancer, Cancer Risk, Case-Control, Case-Control Studies, China, Chinese, Chronic Lymphocytic-Leukemia, Control, Coronary-Heart-Disease, Database, Databases, Factor Tnf, Filtration, Gastric-Cancer, Heterogeneity, Knowledge, Literature, Lta, Lymphotoxin-Alpha, Malignancy, Mar, Meta Analysis, Meta-Analysis, Metaanalysis, Non-Hodgkin-Lymphoma, North, Odds Ratio, P, Polymorphism, Populations, Preimplantation Genetic Diagnosis, Procedure, Prostate-Cancer, Publications, Pubmed, Risk, Risk Factor, Science, Single-Nucleotide Polymorphisms, Source, Tumor-Necrosis-Factor, Web of Science

? Yan, S.S., Xu, D.H., Wang, P.P., Wang, P., Liu, C.C., Hua, C.J., Jiang, T., Zhang, B., Li, Z.C., Lu, L., Liu, X.Z., Wang, B.J., Zhang, D.H., Zhang, R.S., He, S.H., Sun, B.C. and Wang, X. (2014), MTHFR C677T polymorphism contributes to the risk for gastric cancer. Tumor Biology, 35 (3), 2123-2132.

Full Text: 2014\Tum Bio35, 2123.pdf

Abstract: Methylenetetrahydrofolate reductase (MTHFR) has been demonstrated to be involved in carcinogenesis. Increasing individual studies have investigated the role of MTHFR C677T polymorphism in gastric cancer pathogenesis, but with inconsistent findings. The aim of this study was to clarify the potential association of the MTHFR C677T polymorphism with gastric cancer risk by pooling all available data from published case-control studies. We searched the PubMed, Embase, Web of Science, and Wanfang databases for all relevant publications to date. The pooled odds ratio (OR) with corresponding 95 % confidence interval (95 % CI) was calculated. Stratified analysis and sensitivity analysis were also carried out to estimate the strength of this association. A total of 25 case-control studies with 6,572 cases and 9,584 controls were retrieved. Overall, the ORs under five contrast models indicated that the MTHFR C677T variant was positively associated with gastric cancer risk (ORT vs. C = 1.21, 95 % CI 1.10-1.34, P (OR) < 0.001; ORTT vs. CC = 1.47, 95 % CI 1.22-1.76, P (OR) < 0.001; ORTC vs. CC = 1.20, 95 % CI 1.03-1.40, P (OR) = 0.022; ORTT + TC vs. CC = 1.27, 95 % CI 1.10-1.47, P (OR) = 0.001; ORTT vs. CC + TC = 1.29, 95 % CI 1.15-1.46, P (OR) < 0.001). Stratified analyses according to ethnicity and source of controls further confirmed the significant correlations. The current meta-analysis provides strong evidence that the MTHFR C677T polymorphism may be a risk factor for gastric cancer among Asians and Caucasians.

Keywords: Analyses, Analysis, Association, Cancer, Cancer Risk, Cardia Cancer, Case-Control, Case-Control Studies, Colorectal-Cancer, Confidence, Correlations, Data, Databases, Ethnicity, Evidence, Folate, Gastric, Gastric Cancer, Genetic Polymorphisms, Graphical Test, Interval, Italian Population, Korean Population, Mar, Meta Analysis, Meta-Analysis, Metaanalysis, Methylenetetrahydrofolate Reductase, Methylenetetrahydrofolate Reductase C677T, Models, MTHFR C677T, Odds Ratio, P, Pathogenesis, Polymorphism, Polymorphisms, Potential, Publications, Pubmed, Risk, Risk Factor, Role, Science, Sensitivity, Sensitivity Analysis, Source, Stomach-Cancer, Strength, Susceptibility, Web of Science

? Shen, K.R., Zhang, S.D., Zhao, L. and Yang, B.B. (2014), Role of EGFR as a prognostic factor for survival in head and neck cancer: a meta-analysis. Tumor Biology, 35 (3), 2285-2295.

Full Text: 2014\Tum Bio35, 2285.pdf

Abstract: the prognostic role of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinoma (HNSCC) remains controversial. The goal of this study was to summarize existing evidence regarding whether EGFR overexpression is a prognostic factor in HNSCC. Relevant studies were identified using Pubmed, Ovid, and Web of Science databases. A meta-analysis was conducted on the prognostic value of EGFR expression for overall survival (OS) and disease-free survival (DFS). Thirty-seven studies were included. Primary analysis indicated that EGFR overexpression was associated with reduced OS (hazard ratio [HR]: 1.694, 95 % confidence interval [CI]: 1.432-2.004). DFS, on the other hand, was not associated with EGFR expression after adjusting for publication bias (HR: 1.084, 95 % CI: 0.910-1.290). Subgroup analysis gave a statistically significant pooled HR for OS in laryngeal carcinoma (HR: 2.519, 95 % CI: 1.615-3.928) and in oropharyngeal carcinoma (HR: 2.078, 95 % CI: 1.605-2.690). The pooled HR was statistically significant for DFS with respect to oropharyngeal carcinoma (HR: 1.055, 95 % CI: 1.020-1.092), but not laryngeal carcinoma (HR: 1.750, 95 % CI: 0.911-3.360). When dividing studies based on the immunohistochemistry (IHC) scoring system, only the group that evaluated EGFR expression according to the intensity and extent of staining showed no between-study heterogeneity for both OS and DFS. Overall, EGFR overexpression was associated with shortened OS, but not DFS. Future studies are needed that stratify patients by specific tumor sites. Furthermore, when estimating protein level by the IHC method, it is advisable to consider both intensity and extent of staining.

Keywords: Analysis, Bias, Cancer, Carcinoma, Cell, Confidence, Databases, Egfr, End-Points, Epidermal Growth Factor, Evidence, Expression, Factor-Alpha, Gene Copy Number, Growth, Growth Factor, Growth-Factor Receptor, Hazard, Head and Neck Cancer, Heterogeneity, Hnscc, Human-Papillomavirus, Immunohistochemistry, Intensity, Interval, Mar, Meta Analysis, Meta-Analysis, Metaanalysis, Neck, Oral-Cavity, Oropharyngeal Cancer, Patients, Prognostic, Prognostic Factor, Protein, Protein Overexpression, Publication, Publication Bias, Role, Science, Scoring System, Squamous Cell Carcinoma, Squamous-Cell Carcinoma, Survival, Tumor, Value, Web of Science, Web of Science Databases

? Zheng, Q.C., Chen, R.Y., Luan, L.Q., Li, J.R. and Gao, S.L. (2014), The polymorphism of EGFR 142285G > A exerts no risk effect on breast cancer. Tumor Biology,